Portal de Periódicos da CAPES

Donepezil Protects Against Doxorubicin-Induced Chemobrain in Rats via Attenuation of Inflammation and Oxidative Stress Without Interfering With Doxorubicin Efficacy

2021; Springer Science+Business Media; Volume: 18; Issue: 3 Linguagem: Inglês

10.1007/s13311-021-01092-9

1933-7213

Benjamin Ongnok, Thawatchai Khuanjing, Titikorn Chunchai, Patcharapong Pantiya, Sasiwan Kerdphoo, Busarin Arunsak, Wichwara Nawara, Thidarat Jaiwongkam, Nattayaporn Apaijai, Nipon Chattipakorn, Siriporn C. Chattipakorn,

Chemotherapy-induced cardiotoxicity and mitigation

Although doxorubicin (Dox) is an effective chemotherapy medication used extensively in the treatment of breast cancer, it frequently causes debilitating neurological deficits known as chemobrain. Donepezil (DPZ), an acetylcholinesterase inhibitor, provides therapeutic benefits in various neuropathological conditions. However, comprehensive mechanistic insights regarding the neuroprotection of DPZ on cognition and brain pathologies in a Dox-induced chemobrain model remain obscure. Here, we demonstrated that Dox-treated rats manifested conspicuous cognitive deficits and developed chemobrain pathologies as indicated by brain inflammatory and oxidative insults, glial activation, defective mitochondrial homeostasis, increased potential lesions associated with Alzheimer’s disease, disrupted neurogenesis, loss of dendritic spines, and ultimately neuronal death through both apoptosis and necroptosis. Intervention with DPZ co-treatment completely restored cognitive function by attenuating these pathological conditions induced by DOX. We also confirmed that DPZ treatment does not affect the anti-cancer efficacy of Dox in breast cancer cells. Together, our findings suggest that DPZ treatment confers potential neuroprotection against Dox-induced chemobrain.